4.7 Article

Interval cancers after colonoscopy-insights and recommendations

期刊

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrgastro.2012.136

关键词

-

资金

  1. Center for Translational Molecular Medicine

向作者/读者索取更多资源

Several studies have raised warnings about the limited effectiveness of colonoscopy for the prevention of colorectal cancer (CRC), especially of the proximal colon. Two major categories of factors might be responsible for the development of interval cancers, namely technical, endoscopist-dependent factors and biological characteristics of the cancer that lead to more rapid tumour progression. Recognition of endoscopist-dependent factors is critical, as these factors are probably amenable to correction through improved awareness and education of endoscopists, using quality metrics (such as adenoma detection rates and cecal intubation rates) for objective evaluation and feedback. In this article, the current literature regarding the incidence of, and potential explanations for, interval CRCs is outlined. Although there is probably an interaction between technical and biology-related factors-and an attempt to dissect the biology from the technology might be fraught with difficulties-a structured analysis of individual cases of interval cancer might help in the continuous monitoring of the quality of colonoscopy, and ultimately might reduce the number of interval CRCs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pathology

Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice

Elisabeth M. P. Steeghs, Geraldine R. Vink, Marloes A. G. Elferink, Quirinus J. M. Voorham, Hans Gelderblom, Iris D. Nagtegaal, Katrien Grunberg, Marjolijn J. L. Ligtenberg

Summary: The study in the Netherlands showed an increase in mutation testing rates for CRC patients over time, with anti-EGFR therapy mainly used in KRAS/NRAS wild-type patients after the third treatment line. The national average mutation rate was 63.9%, and NGS-based approaches detected more potential biomarkers.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Article Oncology

The earliest events in BRAF-mutant colorectal cancer: exome sequencing of sessile serrated lesions with a tiny focus dysplasia or cancer reveals recurring mutations in two distinct progression pathways

Arne G. C. Bleijenberg, Joep E. G. IJspeert, Jos B. G. Mulder, Paul Drillenburg, Herbert Stel, Elisabeth M. Lodder, Beatriz Carvalho, Jade Jansen, Gerrit Meijer, Susanne van Eeden, Evelien Dekker, Carel J. M. van Noesel

Summary: Around 15-30% of colorectal cancers (CRC) develop from sessile serrated lesions (SSLs). The molecular events and mutations differ between MLH1-proficient and MLH1-deficient lesions, with a higher tumor mutational burden observed in MLH1-deficient lesions. ACVR2A and RNF43/ZNRF3 hotspot mutations are common in the early progression of MLH1-deficient serrated pathway, while APC and TP53 mutations are early events in the MLH1-proficient pathway.

JOURNAL OF PATHOLOGY (2022)

Review Oncology

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies

Samantha Brown, Jessica A. Lavery, Ronglai Shen, Axel S. Martin, Kenneth L. Kehl, Shawn M. Sweeney, Eva M. Lepisto, Hira Rizvi, Caroline G. McCarthy, Nikolaus Schultz, Jeremy L. Warner, Ben Ho Park, Philippe L. Bedard, Gregory J. Riely, Deborah Schrag, Katherine S. Panageas

Summary: Real-world data combining clinical and genomic information may face issues of left truncation, and ignoring this can lead to overestimation of survival rates. Appropriate statistical methods should be applied to ensure valid and meaningful research findings when analyzing clinicogenomic data.

JAMA ONCOLOGY (2022)

Article Oncology

Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients

Luuk J. Schipper, Kim Monkhorst, Kris G. Samsom, Linda J. W. Bosch, Petur Snaebjornsson, Hester van Boven, Paul Roepman, Lizet E. van der Kolk, Winan J. van Houdt, Winette T. A. van der Graaf, Gerrit A. Meijer, Emile E. Voest

Summary: Whole genome sequencing (WGS) can uncover potential diagnostic and actionable genomic characteristics in sarcoma patients that are often overlooked, providing valuable information for clinical decision making.

CANCERS (2022)

Article Gastroenterology & Hepatology

Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study

Emilie C. H. Breekveldt, Iris Lansdorp-Vogelaar, Esther Toes-Zoutendijk, Manon C. W. Spaander, Anneke J. van Vuuren, Folkert J. van Kemenade, Christian R. B. Ramakers, Evelien Dekker, Iris Nagtegaal, Myrtle F. Krul, Niels F. M. Kok, Koert F. D. Kuhlmann, Geraldine R. Vink, Monique E. van Leerdam, Marloes A. G. Elferink

Summary: This study evaluated the changes in colorectal cancer (CRC) incidence, mortality, and treatment before and after the introduction of a screening programme in the Netherlands. Results showed a decrease in overall and advanced-stage CRC incidence after the introduction of the screening programme, with more screening-detected tumors located in the left side of the colon and detected at an early stage.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Oncology

Genome Nexus: A Comprehensive Resource for the Annotation and Interpretation of Genomic Variants in Cancer

Ino de Bruijn, Xiang Li, Selcuk Onur Sumer, Benjamin Gross, Robert Sheridan, Angelica Ochoa, Manda Wilson, Avery Wang, Hongxin Zhang, Aaron Lisman, Adam Abeshouse, Emily Zhang, Alice Thum, Ananthan Sadagopan, Zachary Heins, Cyriac Kandoth, Sander Rodenburg, Sander Tan, Pieter Lukasse, Sjoerd van Hagen, Remond J. A. Fijneman, Gerrit A. Meijer, Nikolaus Schultz, Jianjiong Gao

Summary: Genome Nexus is a user-friendly tool for variant annotation specifically designed for cancer research and clinical practice, addressing the issue of fragmented variant interpretation information across multiple databases, with high-performance annotation capabilities.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors

Berbel L. M. Ykema, Emilie C. H. Breekveldt, Beatriz Carvalho, Tom van Wezel, Gerrit A. Meijer, Martijn Kerst, Michael Schaapveld, Flora E. van Leeuwen, Petur Snaebjornsson, Monique E. van Leerdam

Summary: This study found a higher prevalence of MMRd CRC among non-seminoma testicular cancer survivors. These MMRd CRCs were more often caused by somatic mutations or loss of heterozygosity compared to primary CRC. Exposure to anticancer treatments appears to be associated with the development of these rare MMRd CRC among cancer survivors.

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Berbel L. M. Ykema, Andrea Gini, Lisanne S. Rigter, Manon C. W. Spaander, Leon M. G. Moons, Tanya M. Bisseling, Jan Paul de Boer, Wieke H. M. Verbeek, Pieternella J. Lugtenburg, Cecile P. M. Janus, Eefke J. Petersen, Judith M. Roesink, Richard W. M. van der Maazen, Berthe M. P. Aleman, Gerrit A. Meijer, Flora E. van Leeuwen, Petur Snaebjornsson, Beatriz Carvalho, Monique E. van Leerdam, Iris Lansdorp-Vogelaar

Summary: Colorectal cancer surveillance is cost-effective for Hodgkin lymphoma survivors, and it should start earlier than population screening programs. FIT surveillance is the most cost-effective strategy for all subgroups.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Gastroenterology & Hepatology

Initial Impact of National CRC Screening on Incidence and Advanced Colorectal Cancer

Myrtle F. Krul, Marloes A. G. Elferink, Niels F. M. Kok, Evelien Dekker, Iris Lansdorp-Vogelaar, Gerrit A. Meijer, Iris D. Nagtegaal, Emilie C. H. Breekveldt, Theo J. M. Ruers, Monique E. van Leerdam, Koert F. D. Kuhlmann

Summary: The nationwide CRC screening program in the Netherlands, started in 2014, has shown a significant reduction in the incidence of stage II and IV CRC. Patients with screen-detected CRCs had improved survival and less extensive disease compared to clinically detected cases.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Oncology

Overexpression of the miR-17-92 cluster in colorectal adenoma organoids causes a carcinoma-like gene expression signature

Sanne R. Martens-de Kemp, Malgorzata A. Komor, Rosa Hegi, Anne S. Bolijn, Marianne Tijssen, Florence L. M. de Groen, Annekatrien Depla, Monique van Leerdam, Gerrit A. Meijer, Remond J. A. Fijneman, Beatriz Carvalho

Summary: Gain of chromosome arm 13q and overexpression of miR-17-92 cluster are associated with colorectal adenoma-to-carcinoma progression. However, overexpression of miR-17-92 alone is insufficient to cause malignancy.

NEOPLASIA (2022)

Article Oncology

The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design

P. H. A. Wisse, W. de Klaver, F. van Wifferen, L. Meiqari, M. Bierkens, M. J. E. Greuter, B. Carvalho, M. E. van Leerdam, M. C. W. Spaander, E. Dekker, V. M. H. Coupe, M. de Wit, G. A. Meijer

Summary: This study aims to validate the relative sensitivity of mtFIT compared to FIT in colorectal cancer (CRC) screening, and predict the lifetime health effects and costs using the Adenoma and Serrated Pathway to Colorectal CAncer model. The results of this study will provide important clinical utility information for the Dutch national CRC screening program.

BMC CANCER (2022)

Article Oncology

Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells

Iris van 't Erve, Jamie E. Medina, Alessandro Leal, Eniko Papp, Jillian Phallen, Vilmos Adleff, Elaine Jiayuee Chiao, Adith S. Arun, Karen Bolhuis, John K. Simmons, Aanavi Karandikar, Kenneth C. Valkenburg, Mark Sausen, Samuel Angiuoli, Robert B. Scharpf, Cornelis J. A. Punt, Gerrit A. Meijer, Victor E. Velculescu, Remond J. A. Fijneman

Summary: The study demonstrates that accurate monitoring of treatment response using ctDNA can be achieved in a tumor tissue-independent manner by combining cfDNA and patient-matched WBC genomic DNA analysis. This approach prevents false-positives caused by germline or hematopoietic variants and provides more predictive information on overall survival compared to standard radiological evaluation. Additionally, ctDNA analysis reveals potential therapy resistance mutations in a significant portion of patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Tumour break load is a biologically relevant feature of genomic instability with prognostic value in colorectal cancer

Soufyan Lakbir, Sara Lahoz, Miriam Cuatrecasas, Jordi Camps, Roel A. Glas, Jaap Heringa, Gerrit A. Meijer, Sanne Abeln, Remond J. A. Fijneman

Summary: The study demonstrates that tumor breakload (TBL) is an important prognostic biomarker in colorectal cancer, impacting tumor biology and predicting disease recurrence.

EUROPEAN JOURNAL OF CANCER (2022)

Article Pathology

A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice

Astrid Kramer, Ed Schuuring, Daan C. L. Vessies, Paul van der Leest, Maartje J. Geerlings, Pim Rozendal, Mirthe Lanfermeijer, Theodora C. Linders, Leon C. van Kempen, Remond J. A. Fijneman, Marjolijn J. L. Ligtenberg, Gerrit A. Meijer, Daan van den Broek, Valesca P. Retel, Veerle M. H. Coup

Summary: This study developed a micro-costing framework for consistent cost calculation of ctDNA testing. The framework takes into account the complete diagnostic workflow of ctDNA testing, including costs for personnel, materials, equipment, overhead, and failures. Evaluations and case studies were performed, showing a wide range of costs per sample and the sensitivity to platform, setting, and testing volume. An open access tool is provided for laboratory-specific calculations and exploring the total costs and impact of alternative prices or assumptions.

JOURNAL OF MOLECULAR DIAGNOSTICS (2023)

Article Gastroenterology & Hepatology

An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles

Robert S. Bresalier, Carlo Senore, Graeme P. Young, James Allison, Robert Benamouzig, Sally Benton, Patrick M. M. Bossuyt, Luis Caro, Beatriz Carvalho, Han-Mo Chiu, Veerle M. H. Coupe, Willemijn de Klaver, Clasine Maria de Klerk, Evelien Dekker, Sunil Dolwani, Callum G. Fraser, William Grady, Lydia Guittet, Samir Gupta, Stephen P. Halloran, Ulrike Haug, Geir Hoff, Steven Itzkowitz, Tim Kortlever, Anastasios Koulaouzidis, Uri Ladabaum, Beatrice Lauby-Secretan, Marcis Leja, Bernard Levin, Theodore Robert Levin, Finlay Macrae, Gerrit A. Meijer, Joshua Melson, Colm O'Morain, Susan Parry, Linda Rabeneck, David F. Ransohoff, Roque Saenz, Hiroshi Saito, Silvia Sanduleanu-Dascalescu, Robert E. Schoen, Kevin Selby, Harminder Singh, Robert J. C. Steele, Joseph J. Y. Sung, Erin Leigh Symonds, Sidney J. Winawer

Summary: New non-invasive tests for colorectal cancer (CRC) are emerging, making it challenging to conduct trials with mortality reduction as the main goal. A formal consensus approach involving experts resulted in the revision of previously established principles and the emergence of twelve new principles. The effectiveness of a new test can be evaluated by comparing it with an established non-invasive test, with the faecal immunochemical test considered as the appropriate comparator. Flexible adjustment of the new test's positivity threshold is desirable to meet different screening goals and requirements. A four-phased approach is proposed for the evaluation of new tests, including small studies, prospective estimation of accuracy, evaluation in screening populations, and monitoring for missed lesions.
暂无数据